30-Jul-2025 1:41 AM CST - Business Wire Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the first quarter of fiscal year 2025 (three months ended June 30, 2025), with generic erosion of VYVANSE significantly impacting revenue and Core Operating Profit in line with company expectations for the quarter. The company expects these impacts to moderate in future quarters. Takeda also achieved several important milestones in its R&D pipeline, reinforcing its long-term growth trajectory an
8-May-2025 1:36 AM CST - Business Wire Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2024 (period ended March 31, 2025) with continued strong momentum in Growth & Launch Products offsetting loss of exclusivity impact to drive revenue and Core Operating Profit growth, supported by robust cost management. Takeda has built a high-value late-stage pipeline with potentially life-transforming new treatment options for patients. Following a positive Phase 3 readout for rus
3-Mar-2025 5:45 AM CST - Business Wire Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera Protagonist Therapeutics, Inc. (Protagonist) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) today announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera (PV) were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment. The study met its primary endpoint and all four key secondary endpoints. Rusfertide is a first
30-Jan-2025 12:35 AM CST - Business Wire Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2024 (nine months ended December 31, 2024) showing continued advancement of its Growth & Launch Products, which delivered double-digit growth of 14.6% at CER. The company has upgraded its full year outlook for growth, reflecting strong year-to-date product performance and OPEX efficiencies, as well as revised foreign exchange assumptions. Takeda continues to adva
31-Oct-2024 11:45 PM CST - Business Wire Takeda anuncia resultados slidos no primeiro semestre do ano fiscal de 2024 e aumenta a perspectiva para o ano inteiro A Takeda (TOKYO:4502/NYSE:TAK) anunciou hoje os resultados do primeiro semestre do ano fiscal de 2024 (seis meses encerrados em 30 de setembro de 2024), com o impulso contnuo de seus Produtos de crescimento e lanamento. A empresa atualizou suas previses para o ano inteiro e diretrizes de administrao para refletir um desempenho mais forte do que o previsto no primeiro semestre (incluindo uma eroso de genricos do VYVANSE nos EUA mais branda do que o previst
31-Oct-2024 11:10 PM CST - Business Wire Takeda anuncia slidos resultados del primer semestre (S1) del ejercicio fiscal 2024 y eleva sus perspectivas para el ao completo Takeda (TOKYO:4502/NYSE:TAK) ha dado a conocer hoy los resultados del primer semestre del ao fiscal 2024 (seis meses finalizados el 30 de septiembre de 2024), con un impulso continuado en sus Productos de crecimiento y lanzamiento que favorecen el crecimiento. La empresa ha mejorado sus previsiones para todo el ao y las directrices de la direccin para reflejar unos resultados del primer semestre mejores de lo esperado (incluida una erosin de los genricos de V
30-Jul-2025 1:41 AM CST - Business Wire Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the first quarter of fiscal year 2025 (three months ended June 30, 2025), with generic erosion of VYVANSE significantly impacting revenue and Core Operating Profit in line with company expectations for the quarter. The company expects these impacts to moderate in future quarters. Takeda also achieved several important milestones in its R&D pipeline, reinforcing its long-term growth trajectory an
8-May-2025 1:36 AM CST - Business Wire Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2024 (period ended March 31, 2025) with continued strong momentum in Growth & Launch Products offsetting loss of exclusivity impact to drive revenue and Core Operating Profit growth, supported by robust cost management. Takeda has built a high-value late-stage pipeline with potentially life-transforming new treatment options for patients. Following a positive Phase 3 readout for rus
3-Mar-2025 5:45 AM CST - Business Wire Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera Protagonist Therapeutics, Inc. (Protagonist) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) today announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera (PV) were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment. The study met its primary endpoint and all four key secondary endpoints. Rusfertide is a first
30-Jan-2025 12:35 AM CST - Business Wire Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2024 (nine months ended December 31, 2024) showing continued advancement of its Growth & Launch Products, which delivered double-digit growth of 14.6% at CER. The company has upgraded its full year outlook for growth, reflecting strong year-to-date product performance and OPEX efficiencies, as well as revised foreign exchange assumptions. Takeda continues to adva
31-Oct-2024 11:45 PM CST - Business Wire Takeda anuncia resultados slidos no primeiro semestre do ano fiscal de 2024 e aumenta a perspectiva para o ano inteiro A Takeda (TOKYO:4502/NYSE:TAK) anunciou hoje os resultados do primeiro semestre do ano fiscal de 2024 (seis meses encerrados em 30 de setembro de 2024), com o impulso contnuo de seus Produtos de crescimento e lanamento. A empresa atualizou suas previses para o ano inteiro e diretrizes de administrao para refletir um desempenho mais forte do que o previsto no primeiro semestre (incluindo uma eroso de genricos do VYVANSE nos EUA mais branda do que o previst
31-Oct-2024 11:10 PM CST - Business Wire Takeda anuncia slidos resultados del primer semestre (S1) del ejercicio fiscal 2024 y eleva sus perspectivas para el ao completo Takeda (TOKYO:4502/NYSE:TAK) ha dado a conocer hoy los resultados del primer semestre del ao fiscal 2024 (seis meses finalizados el 30 de septiembre de 2024), con un impulso continuado en sus Productos de crecimiento y lanzamiento que favorecen el crecimiento. La empresa ha mejorado sus previsiones para todo el ao y las directrices de la direccin para reflejar unos resultados del primer semestre mejores de lo esperado (incluida una erosin de los genricos de V
